Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signature.

Drukker CA, van den Hout HC, Sonke GS, Brain E, Bonnefoi H, Cardoso F, Goldhirsch A, Harbeck N, Honkoop AH, Koornstra RH, van Laarhoven HW, Portielje JE, Schneeweiss A, Smorenburg CH, Stouthard J, Linn SC, Schmidt MK.

Eur J Cancer. 2014 Apr;50(6):1045-54. doi: 10.1016/j.ejca.2014.01.016. Epub 2014 Feb 13.

2.

Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms.

Drukker CA, Nijenhuis MV, Bueno-de-Mesquita JM, Retèl VP, van Harten WH, van Tinteren H, Wesseling J, Schmidt MK, Van't Veer LJ, Sonke GS, Rutgers EJ, van de Vijver MJ, Linn SC.

Breast Cancer Res Treat. 2014 Jun;145(3):697-705. doi: 10.1007/s10549-014-2954-2. Epub 2014 Apr 24.

3.

Perspectives and attitudes on the use of adjuvant chemotherapy and trastuzumab in older adults with HER-2+ breast cancer: a survey of oncologists.

Hurria A, Wong FL, Pal S, Chung CT, Bhatia S, Mortimer J, Somlo G, Hurvitz S, Villaluna D, Naeim A.

Oncologist. 2009 Sep;14(9):883-90. doi: 10.1634/theoncologist.2009-0056. Epub 2009 Sep 2.

4.

Health-related quality of life in early breast cancer.

Groenvold M.

Dan Med Bull. 2010 Sep;57(9):B4184.

PMID:
20816024
5.

Adjuvant treatment recommendations in older women with breast cancer: a survey of oncologists.

Hurria A, Naeim A, Elkin E, Limaye S, Grover A, Hudis C, Pearce C, Robson M.

Crit Rev Oncol Hematol. 2007 Mar;61(3):255-60. Epub 2006 Nov 13.

PMID:
17098441
6.

Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.

Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, Hasmüller S, Kiechle M, Jänicke F, Thomssen C; Chemo-N 0 Study Group.

Eur J Cancer. 2013 May;49(8):1825-35. doi: 10.1016/j.ejca.2013.01.007. Epub 2013 Mar 13.

PMID:
23490655
7.

Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer.

Martín M, González-Rivera M, Morales S, de la Haba-Rodriguez J, González-Cortijo L, Manso L, Albanell J, González-Martín A, González S, Arcusa A, de la Cruz-Merino L, Rojo F, Vidal M, Galván P, Aguirre E, Morales C, Ferree S, Pompilio K, Casas M, Caballero R, Goicoechea U, Carrasco E, Michalopoulos S, Hornberger J, Prat A.

Curr Med Res Opin. 2015 Jun;31(6):1129-37. doi: 10.1185/03007995.2015.1037730. Epub 2015 Apr 23.

PMID:
25851308
8.

Oncologists' recommendations for adjuvant therapy in hormone receptor-positive breast cancer patients of varying age and health status.

Naeim A, Wong FL, Pal SK, Hurria A.

Clin Breast Cancer. 2010 Apr;10(2):136-43. doi: 10.3816/CBC.2010.n.018.

9.

Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.

Blohmer JU, Rezai M, Kümmel S, Kühn T, Warm M, Friedrichs K, Benkow A, Valentine WJ, Eiermann W.

J Med Econ. 2013;16(1):30-40. doi: 10.3111/13696998.2012.722572. Epub 2012 Sep 11.

PMID:
22966753
10.

The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer.

de Boer RH, Baker C, Speakman D, Chao CY, Yoshizawa C, Mann GB.

Med J Aust. 2013 Aug 5;199(3):205-8.

PMID:
23909545
11.

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer.

Knauer M, Mook S, Rutgers EJ, Bender RA, Hauptmann M, van de Vijver MJ, Koornstra RH, Bueno-de-Mesquita JM, Linn SC, van 't Veer LJ.

Breast Cancer Res Treat. 2010 Apr;120(3):655-61. doi: 10.1007/s10549-010-0814-2. Epub 2010 Mar 5.

PMID:
20204499
12.

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

Bueno-de-Mesquita JM, van Harten WH, Retel VP, van 't Veer LJ, van Dam FS, Karsenberg K, Douma KF, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJ, Brink G, Floore AN, Glas AM, Roumen RM, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC.

Lancet Oncol. 2007 Dec;8(12):1079-1087. doi: 10.1016/S1470-2045(07)70346-7. Epub 2007 Nov 26. Erratum in: Lancet Oncol. 2008 Jan;9(1):10.

PMID:
18042430
13.

ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.

Roberts MC, Bryson A, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes K, Wheeler SB.

Int J Technol Assess Health Care. 2016 Jan;32(5):355-361. doi: 10.1017/S026646231600060X. Epub 2016 Dec 13.

PMID:
27958190
14.

Integrated gene expression profile predicts prognosis of breast cancer patients.

Li LF, Xu XJ, Zhao Y, Liu ZB, Shen ZZ, Jin WR, Shao ZM.

Breast Cancer Res Treat. 2009 Jan;113(2):231-7. doi: 10.1007/s10549-008-9925-4. Epub 2008 Feb 16.

PMID:
18278552
15.

Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.

Albain KS, Paik S, van't Veer L.

Breast. 2009 Oct;18 Suppl 3:S141-5. doi: 10.1016/S0960-9776(09)70290-5. Review.

PMID:
19914534
16.

Early breast cancer in the elderly: assessment and management considerations.

Albrand G, Terret C.

Drugs Aging. 2008;25(1):35-45. Review.

PMID:
18184027
17.

Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer.

Whelan T, Sawka C, Levine M, Gafni A, Reyno L, Willan A, Julian J, Dent S, Abu-Zahra H, Chouinard E, Tozer R, Pritchard K, Bodendorfer I.

J Natl Cancer Inst. 2003 Apr 16;95(8):581-7.

PMID:
12697850
18.

Chemotherapy for advanced breast cancer: what influences oncologists' decision-making?

Grunfeld EA, Ramirez AJ, Maher EJ, Peach D, Young T, Albery IP, Richards MA.

Br J Cancer. 2001 May 4;84(9):1172-8.

19.

Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers.

Hurria A, Wong FL, Villaluna D, Bhatia S, Chung CT, Mortimer J, Hurvitz S, Naeim A.

J Clin Oncol. 2008 Nov 20;26(33):5386-92. doi: 10.1200/JCO.2008.17.6891. Epub 2008 Oct 27.

20.

Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancer.

Conlin AK, Seidman AD.

Mol Diagn Ther. 2007;11(6):355-60. Review.

PMID:
18078353

Supplemental Content

Support Center